Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology firm supplying devices, instruments and reagents used by hospitals, laboratories and life‑science researchers. Its portfolio includes needles and syringes, medication‑management systems, diagnostic instruments and biosciences tools, producing a high share of recurring revenue and relatively predictable cash flows. With a market capitalisation of around $54.18 billion, BDX benefits from steady demand driven by hospital procedures, chronic disease management and diagnostic testing. Investors tend to focus on margin trends, capital allocation (dividends and buybacks), R&D and acquisition activity. Key risks include regulatory scrutiny, litigation, reimbursement pressure and sensitivity to hospital capital spending and global economic conditions. Longer‑term growth is supported by demographic trends and ongoing innovation in diagnostics, though past performance is not a reliable indicator of future returns. This is general educational information only and not personalised investment advice; suitability depends on your individual circumstances.
Why It's Moving
Becton Dickinson Shows Undervaluation Signals as Analysts Narrow Forecast Range Around $223 Fair Value
- Valuation analysis scores BDX 5 out of 6 for being undervalued, with intrinsic value estimated at roughly $224 per share versus the current trading price, indicating meaningful gap for value-conscious investors
- Stock has retreated 14.4% over the past month amid broader healthcare sector volatility, though it maintains a 3.3% gain over the past week as investors reassess risk and defensiveness in medical technology holdings
- Analyst targets range from $185 to $280, reflecting divided opinions on the company's transformative merger with Waters Corporation and the planned separation of its Life Sciences division, both reshaping its long-term competitive positioning
Becton Dickinson Shows Undervaluation Signals as Analysts Narrow Forecast Range Around $223 Fair Value
- Valuation analysis scores BDX 5 out of 6 for being undervalued, with intrinsic value estimated at roughly $224 per share versus the current trading price, indicating meaningful gap for value-conscious investors
- Stock has retreated 14.4% over the past month amid broader healthcare sector volatility, though it maintains a 3.3% gain over the past week as investors reassess risk and defensiveness in medical technology holdings
- Analyst targets range from $185 to $280, reflecting divided opinions on the company's transformative merger with Waters Corporation and the planned separation of its Life Sciences division, both reshaping its long-term competitive positioning
When is the next earnings date for Becton, Dickinson and Company (BDX)?
Becton, Dickinson and Company is expected to announce its next earnings report between April 27 and May 7, 2026, with most sources indicating a date around April 29-30, 2026. The report will cover the second quarter of fiscal 2026. Analysts are currently projecting an earnings per share of approximately $2.77 to $2.90 for the quarter. The company has not yet officially confirmed the precise announcement date.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Becton, Dickinson and Company's stock, expecting it to rise in value.
Financial Health
Becton, Dickinson and Company is showing strong revenue and profits, with solid cash generation capabilities.
Dividend
Becton, Dickinson and Company's dividend yield of 2.42% offers a reasonable return for dividend-seeking investors. If you invested $1000 you would be paid $41.70 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BDX
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: September 22, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Revenue Base
BDX earns steady income from disposables and consumables which can smooth earnings, though results can still vary with hospital budgets and competition.
Global Healthcare Exposure
Sales span hospitals, labs and research centres worldwide, offering diversification but exposing the company to currency and regulatory risks.
Innovation & M&A
R&D and targeted acquisitions help expand the product pipeline and market share, though integration and regulatory hurdles can affect outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
